162 related articles for article (PubMed ID: 32698829)
1. Muramyl dipeptide-mediated immunomodulation on monocyte subsets exerts therapeutic effects in a mouse model of Alzheimer's disease.
Fani Maleki A; Cisbani G; Plante MM; Préfontaine P; Laflamme N; Gosselin J; Rivest S
J Neuroinflammation; 2020 Jul; 17(1):218. PubMed ID: 32698829
[TBL] [Abstract][Full Text] [Related]
2. Muramyl Dipeptide Administration Delays Alzheimer's Disease Physiopathology via NOD2 Receptors.
Piec PA; Pons V; Préfontaine P; Rivest S
Cells; 2022 Jul; 11(14):. PubMed ID: 35883683
[TBL] [Abstract][Full Text] [Related]
3. Selective Immunomodulatory and Neuroprotective Effects of a NOD2 Receptor Agonist on Mouse Models of Multiple Sclerosis.
Fani Maleki A; Cisbani G; Laflamme N; Prefontaine P; Plante MM; Baillargeon J; Rangachari M; Gosselin J; Rivest S
Neurotherapeutics; 2021 Apr; 18(2):889-904. PubMed ID: 33479802
[TBL] [Abstract][Full Text] [Related]
4. Tissue-Plasminogen Activator Attenuates Alzheimer's Disease-Related Pathology Development in APPswe/PS1 Mice.
ElAli A; Bordeleau M; Thériault P; Filali M; Lampron A; Rivest S
Neuropsychopharmacology; 2016 Apr; 41(5):1297-307. PubMed ID: 26349911
[TBL] [Abstract][Full Text] [Related]
5. Muramyl dipeptide induces NOD2-dependent Ly6C(high) monocyte recruitment to the lungs and protects against influenza virus infection.
Coulombe F; Fiola S; Akira S; Cormier Y; Gosselin J
PLoS One; 2012; 7(5):e36734. PubMed ID: 22590599
[TBL] [Abstract][Full Text] [Related]
6. Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression.
Al-Onaizi MA; Thériault P; Lecordier S; Prefontaine P; Rivest S; ElAli A
Brain Behav Immun; 2022 Jan; 99():363-382. PubMed ID: 34343617
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of glatiramer acetate and grafted CD115⁺ monocytes in a mouse model of Alzheimer's disease.
Koronyo Y; Salumbides BC; Sheyn J; Pelissier L; Li S; Ljubimov V; Moyseyev M; Daley D; Fuchs DT; Pham M; Black KL; Rentsendorj A; Koronyo-Hamaoui M
Brain; 2015 Aug; 138(Pt 8):2399-422. PubMed ID: 26049087
[TBL] [Abstract][Full Text] [Related]
8. Dihydromyricetin inhibits microglial activation and neuroinflammation by suppressing NLRP3 inflammasome activation in APP/PS1 transgenic mice.
Feng J; Wang JX; Du YH; Liu Y; Zhang W; Chen JF; Liu YJ; Zheng M; Wang KJ; He GQ
CNS Neurosci Ther; 2018 Dec; 24(12):1207-1218. PubMed ID: 29869390
[TBL] [Abstract][Full Text] [Related]
9. D-Ala2GIP facilitated synaptic plasticity and reduces plaque load in aged wild type mice and in an Alzheimer's disease mouse model.
Faivre E; Hölscher C
J Alzheimers Dis; 2013; 35(2):267-83. PubMed ID: 23568101
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model.
Jin WS; Shen LL; Bu XL; Zhang WW; Chen SH; Huang ZL; Xiong JX; Gao CY; Dong Z; He YN; Hu ZA; Zhou HD; Song W; Zhou XF; Wang YZ; Wang YJ
Acta Neuropathol; 2017 Aug; 134(2):207-220. PubMed ID: 28477083
[TBL] [Abstract][Full Text] [Related]
11. The effect of focal brain injury on beta-amyloid plaque deposition, inflammation and synapses in the APP/PS1 mouse model of Alzheimer's disease.
Collins JM; King AE; Woodhouse A; Kirkcaldie MT; Vickers JC
Exp Neurol; 2015 May; 267():219-29. PubMed ID: 25747037
[TBL] [Abstract][Full Text] [Related]
12. Stromal cell-derived factor 1α decreases β-amyloid deposition in Alzheimer's disease mouse model.
Wang Q; Xu Y; Chen JC; Qin YY; Liu M; Liu Y; Xie MJ; Yu ZY; Zhu Z; Wang W
Brain Res; 2012 Jun; 1459():15-26. PubMed ID: 22560596
[TBL] [Abstract][Full Text] [Related]
13. Lack of P-glycoprotein Results in Impairment of Removal of Beta-Amyloid and Increased Intraparenchymal Cerebral Amyloid Angiopathy after Active Immunization in a Transgenic Mouse Model of Alzheimer's Disease.
Bruckmann S; Brenn A; Grube M; Niedrig K; Holtfreter S; von Bohlen und Halbach O; Groschup M; Keller M; Vogelgesang S
Curr Alzheimer Res; 2017; 14(6):656-667. PubMed ID: 27915995
[TBL] [Abstract][Full Text] [Related]
14. Anti-Inflammatory Treatment with FTY720 Starting after Onset of Symptoms Reverses Synaptic Deficits in an AD Mouse Model.
Kartalou GI; Salgueiro-Pereira AR; Endres T; Lesnikova A; Casarotto P; Pousinha P; Delanoe K; Edelmann E; Castrén E; Gottmann K; Marie H; Lessmann V
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255764
[TBL] [Abstract][Full Text] [Related]
15. A modified formulation of Chinese traditional medicine improves memory impairment and reduces Aβ level in the Tg-APPswe/PS1dE9 mouse model of Alzheimer's disease.
Jeon S; Bose S; Hur J; Jun K; Kim YK; Cho KS; Koo BS
J Ethnopharmacol; 2011 Sep; 137(1):783-9. PubMed ID: 21762767
[TBL] [Abstract][Full Text] [Related]
16. Brain Penetrating Bifunctional Erythropoietin-Transferrin Receptor Antibody Fusion Protein for Alzheimer's Disease.
Chang R; Al Maghribi A; Vanderpoel V; Vasilevko V; Cribbs DH; Boado R; Pardridge WM; Sumbria RK
Mol Pharm; 2018 Nov; 15(11):4963-4973. PubMed ID: 30252487
[TBL] [Abstract][Full Text] [Related]
17. Chronic Toxoplasma gondii infection enhances β-amyloid phagocytosis and clearance by recruited monocytes.
Möhle L; Israel N; Paarmann K; Krohn M; Pietkiewicz S; Müller A; Lavrik IN; Buguliskis JS; Schott BH; Schlüter D; Gundelfinger ED; Montag D; Seifert U; Pahnke J; Dunay IR
Acta Neuropathol Commun; 2016 Mar; 4():25. PubMed ID: 26984535
[TBL] [Abstract][Full Text] [Related]
18. Reduction of beta-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease.
Paris D; Ganey NJ; Laporte V; Patel NS; Beaulieu-Abdelahad D; Bachmeier C; March A; Ait-Ghezala G; Mullan MJ
J Neuroinflammation; 2010 Mar; 7():17. PubMed ID: 20211007
[TBL] [Abstract][Full Text] [Related]
19. Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept.
Maezawa I; Nguyen HM; Di Lucente J; Jenkins DP; Singh V; Hilt S; Kim K; Rangaraju S; Levey AI; Wulff H; Jin LW
Brain; 2018 Feb; 141(2):596-612. PubMed ID: 29272333
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease.
Hansen HH; Fabricius K; Barkholt P; Kongsbak-Wismann P; Schlumberger C; Jelsing J; Terwel D; Termont A; Pyke C; Knudsen LB; Vrang N
PLoS One; 2016; 11(7):e0158205. PubMed ID: 27421117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
